thyroid, porcine · THYROID 90 mg/1 · Tablet · Oral · Nivagen Pharmaceuticals, Inc.
NDC 75834-0313-01 · 100 TABLET in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →
4 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $1.00 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market · price up 5% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | THYROID 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | THYROID 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | THYROID 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 240 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 180 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 120 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | SUS SCROFA THYROID 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | THYROID 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 120 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 15 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 180 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 240 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | THYROID 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | SUS SCROFA THYROID 15 mg/1 | Jul 15, 2026 | Sep 1, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Niva Thyroid — NDC 75834-0313-01," retrieved September 3, 2026, https://drugdashboards.com/drug/75834031301.
Free to cite with attribution — see how the data is put together.